

**SUPPLEMENTAL MATERIAL**

**Table S1:** Baseline characteristics for patients in the biomarker substudy of CLARITY-TIMI 28.

<b>Variable</b>	
Number	1250
Gender (male), %	79.4%
Age (years), median (25th, 75th percentile)	58 (50, 67)
Weight (kg), median (25th, 75th percentile)	80 (70, 89)
BMI, median (25th, 75th percentile)	27.1 (24.8, 30.1)
History hypertension, %	39.4
History hyperlipidemia, %	40.8
History diabetes, %	17.4
History CHF, %	1.3
Current tobacco use, %	47.3
Prior MI, %	8.4
Prior PCI, %	4.6
Anterior MI, %	37.5
CrCl, median (25th, 75th percentile)	86.9 (70.2, 106.7)
Sx onset to lytic (hrs), median (25th, 75th percentile)	2.5 (1.7, 3.8)
Killip class 2-4, %	7.0
Fibrin-specific lytic, %	86.7
Initial heparin type, %	
None, %	7.0
UFH, %	44.9
LMWH, %	43.4
Both, %	4.7
Angiography performed during index hospitalization, %	96.0

**Table S2:** Baseline characteristics by NT-proBNP quartile at baseline

<b>Variable</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>p-value (trend)</b>
Number	313	312	312	312	
Ranges (pg/ml)	< 36.4	36.4-93.8	93.8-282.4	>282.4	
Gender (male), %	88.8	83.3	76.6	68.9	<0.001
Age (years), median	51	56	62	65	<0.001
Weight (kg), median	80.0	80.0	80.0	78.0	0.03
BMI, median	27.1	26.8	27.5	27.1	0.44
History hypertension, %	31.1	30.4	44.2	51.6	<0.001
History hyperlipidemia, %	44.5	42.4	41.7	34.1	0.02
History diabetes, %	13.9	15.9	15.4	24.4	0.001
History CHF, %	0.0	0.3	1.0	3.9	<0.001
Current tobacco use, %	54.5	49.7	43.5	41.7	<0.001
Prior MI, %	7.1	5.8	8.4	12.5	0.007
Prior PCI, %	5.1	3.8	3.5	5.8	0.75
Anterior MI, %	31.9	34.0	36.5	47.8	<0.001
CrCl, median	93.2	92.5	84.8	76.6	<0.001
Sx onset to lytic (hrs), median	2.0	2.3	2.6	3.6	<0.001
Killip class 2-4, %	2.6	6.8	5.5	13.2	<0.001
Fibrin-specific lytic, %	89.5	87.2	88.1	82.1	0.01
Initial heparin type, %					
None, %	6.1	5.4	7.1	9.3	0.30
UFH, %	41.2	42.9	50.3	44.9	
LMWH, %	47.3	47.8	37.8	41.0	
Both, %	5.4	3.8	4.8	4.8	
Angiography performed during index hospitalization, %	98.1	98.1	97.1	90.7	<0.001

**Table S3:** Baseline characteristics by quartile of ANP at baseline

<b>Variable</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>p-value (trend)</b>
Number	281	280	280	280	
Ranges (pmol/L)	< 56.2	56.2-108.7	108.7 - 181.7	>181.7	
Gender (male) , %	86.1	82.9	78.2	72.1	<0.001
Age (years), median	54	55	59	65.5	<0.001
Weight (kg), median	84.0	80.0	80.0	77.0	<0.001
BMI, median	27.9	27.0	27.0	26.6	<0.001
History hypertension, %	40.0	36.5	36.9	44.2	0.32
History hyperlipidemia, %	41.6	43.4	41.7	36.9	0.27
History diabetes, %	18.3	16.7	17.6	18.0	0.995
History CHF, %	0.4	0.7	1.1	3.3	0.003
Current tobacco use, %	53.4	51.3	43.0	42.1	0.002
Prior MI, %	6.8	10.0	6.1	10.4	0.35
Prior PCI, %	4.6	5.0	2.5	6.5	0.60
Anterior MI, %	29.9	36.4	37.9	48.2	<0.001
CrCl, median	96.1	95.9	85.9	74.1	<0.001
Sx onset to lytic (hrs), median	2.3	2.5	2.6	2.8	0.06
Killip class 2-4, %	3.9	4.7	7.9	11.5	<0.001
Fibrin-specific lytic, %	82.2	91.1	87.1	85.0	0.62
Initial Heparin Type, %					
None, %	12.1	5.0	5.0	6.8	0.12
UFH, %	43.4	50.4	40.4	45.4	
LMWH, %	40.6	39.6	51.4	41.4	
Both, %	3.9	5.0	3.2	6.4	
Angiography performed during index hospitalizati	95.0	98.6	96.8	92.5	0.08

**Table S4:** Baseline characteristics by ST2 quartile at baseline

<b>Variable</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>p-value (trend)</b>
Number	367	259	305	308	
Ranges (ng/ml)	< 0.004	0.004- 0.08	0.08- 0.33	> 0.33	
Gender (male), %	79.8	80.7	80.3	77.3	0.45
Age (years), median	57	58	59	59	0.06
Weight (kg), median	80.0	80.0	79.8	79.8	0.07
BMI, median	27.4	27.2	26.8	27.0	0.42
History hypertension, %	35.9	37.4	43.7	40.8	0.08
History hyperlipidemia, %	39.3	44.4	42.3	38.3	0.81
History diabetes, %	9.9	18.9	20.5	21.9	<0.001
History CHF, %	1.7	1.5	0.7	1.0	0.28
Current tobacco use, %	50.4	44.8	47.4	45.8	0.31
Prior MI, %	8.5	9.3	9.2	6.9	0.51
Prior PCI, %	5.4	6.2	3.0	3.9	0.14
Anterior MI, %	34.1	37.8	36.4	42.9	0.03
CrCl, median	90.8	88.0	86.0	83.5	0.002
Sx onset to lytic (hrs), median	2.3	2.4	2.7	2.7	<0.001
Killip class 2-4, %	6.3	3.9	8.9	8.8	0.07
Fibrin-specific lytic, %	91.0	86.5	83.9	84.1	0.004
Initial heparin type, %					
None, %	4.4	7.7	6.6	10.1	0.11
UFH, %	42.8	46.7	47.2	43.5	
LMWH, %	46.6	42.9	42.6	41.2	
Both, %	6.3	2.7	3.6	5.2	
Angiography performed during index hospitalization, %	96.7	97.3	95.4	94.5	0.09

**Table S5:** Baseline characteristics by Galectin-3 quartile at baseline

<b>Variable</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>p-value (trend)</b>
Number	260	257	259	258	
Ranges	< 11.7	11.7-14.3	14.3-18.0	> 18.0	
Gender (male) , %	85.4	80.9	81.1	70.5	<0.001
Age (years), median	56	56	60	63	<0.001
Weight (kg), median	80.0	80.0	80.0	80.0	0.48
BMI, median	27.2	26.8	26.8	27.7	0.20
History hypertension, %	31.9	34.6	40.7	47.8	<0.001
History hyperlipidemia, %	41.4	41.4	42.4	37.8	0.50
History diabetes, %	13.8	15.4	19.1	20.4	0.03
History CHF, %	0.8	0.8	1.2	2.3	0.10
Current tobacco use, %	48.5	51.0	46.1	42.0	0.08
Prior MI, %	8.9	8.2	7.0	7.8	0.55
Prior PCI, %	6.5	5.8	3.1	2.7	0.01
Anterior MI, %	36.5	37.0	34.4	43.4	0.18
CrCl, median	97.0	92.4	82.4	76.3	<0.001
Sx onset to lytic (hrs), median	2.4	2.3	2.5	2.8	0.001
Killip class 2-4, %	6.2	7.4	5.0	10.9	0.10
Fibrin-specific lytic, %	88.8	85.2	88.4	82.9	0.13
Initial heparin type, %					
None, %	8.1	9.3	4.2	5.8	0.87
UFH, %	39.2	43.2	48.3	47.3	
LMWH, %	48.5	42.4	43.6	41.5	
Both, %	4.2	5.1	3.9	5.4	
Angiography performed during index hospitalization, %	97.7	96.5	94.6	94.2	0.03

**Table S6:** Baseline characteristics by MR-pro ADM quartile at baseline

<b>Variable</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>p-value (trend)</b>
Number	282	281	282	281	
Ranges (nmol/L)	< 0.13	0.13-0.47	0.47-0.62	>0.62	
Gender (male) , %	83.3	81.5	82.3	72.2	0.002
Age (years), median	59	54	56	65	<0.001
Weight (kg), median	81.0	78.0	80.0	80.0	0.63
BMI, median	27.2	26.8	27.0	27.7	0.44
History hypertension, %	39.9	32.0	33.2	51.6	0.006
History hyperlipidemia, %	36.5	41.4	43.5	41.9	0.18
History diabetes, %	17.4	11.9	17.2	24.5	0.01
History CHF, %	1.1	0.0	0.7	3.6	0.007
Current tobacco use, %	45.9	50.4	53.2	40.6	0.32
Prior MI, %	7.5	7.1	7.9	10.8	0.15
Prior PCI, %	3.9	2.8	7.1	4.6	0.25
Anterior MI, %	32.3	33.5	42.6	44.8	<0.001
CrCl, median	86.3	96.5	91.8	76.1	<0.001
Sx onset to lytic (hrs), median	2.5	2.3	2.5	2.9	<0.001
Killip class 2-4, %	4.6	6.1	6.4	10.4	0.01
Fibrin-specific lytic, %	83.3	90.4	87.9	84.0	0.96
Initial heparin type, %					
None, %	11.3	4.3	6.0	7.1	0.55
UFH, %	47.2	44.1	44.7	42.7	
LMWH, %	37.9	45.2	44.3	46.6	
Both, %	3.5	6.4	5.0	3.6	
Angiography performed during index hospitalization, %	94.3	96.1	98.2	94.3	0.70

**Table S7:** Baseline characteristics by copeptin quartile at baseline

<b>Variable</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>p-value (trend)</b>
Copeptin	282	281	282	281	
Ranges (pmol/L)	< 24.4	24.4-71.2	71.2-160.4	>160.4	
Gender (male) , %	81.6	78.6	83.3	75.8	0.24
Age (years), median	57	58	58	61	<0.001
Weight (kg), median	80.0	81.0	80.0	77.0	<0.001
BMI, median	27.8	27.5	26.8	26.2	<0.001
History hypertension, %	37.9	40.5	39.1	39.0	0.87
History hyperlipidemia, %	40.3	38.5	43.9	40.8	0.62
History diabetes, %	21.4	16.8	15.1	17.6	0.19
History CHF, %	1.4	1.4	1.4	1.1	0.73
Current tobacco use, %	51.2	46.3	50.7	42.5	0.10
Prior MI, %	6.8	11.7	7.8	7.1	0.69
Prior PCI, %	6.0	5.3	3.5	3.6	0.10
Anterior MI, %	42.2	38.4	33.3	38.8	0.24
CrCl, median	95.5	91.1	87.1	77.1	<0.001
Sx onset to lytic (hrs), median	3.2	2.7	2.4	2.0	<0.001
Killip class 2-4, %	6.0	5.7	7.5	8.6	0.17
Fibrin-specific lytic, %	85.8	88.3	85.8	86.5	0.96
Initial heparin type, %					
None, %	7.8	6.0	7.4	7.1	0.89
UFH, %	42.9	47.7	42.9	46.3	
LMWH, %	46.1	40.9	45.7	40.6	
Both, %	3.2	5.3	3.9	6.0	
Angiography performed during index hospitalization, %	96.1	97.2	95.0	94.7	0.23



**Table S8:** Baseline characteristics by MPO quartile at baseline

<b>Variable</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>p-value (trend)</b>
Number	262	261	261	261	
Ranges (ng/ml)	< 29.4	29.4-91.8	91.8-301.4	>301.4	
Gender (male) , %	78.2	78.9	81.2	80.5	0.42
Age (years), median	57	59	59	59	0.24
Weight (kg), median	79.7	80.0	80.0	80.0	0.44
BMI, median	26.8	26.8	27.0	27.4	0.30
History hypertension, %	31.9	39.7	37.3	45.4	0.005
History hyperlipidemia, %	37.1	41.6	44.3	39.8	0.46
History diabetes, %	14.6	20.7	16.9	16.3	0.89
History CHF, %	0.8	1.9	1.1	1.2	0.90
Current tobacco use, %	45.4	48.7	46.4	47.5	0.78
Prior MI, %	8.8	9.2	6.9	6.9	0.28
Prior PCI, %	6.1	5.4	3.4	3.1	0.054
Anterior MI, %	38.5	37.9	38.3	36.0	0.59
CrCl, median	93.3	83.3	87.6	84.7	0.06
Sx onset to lytic (hrs), median	2.4	2.5	2.5	2.5	0.08
Killip class 2-4, %	4.6	9.6	10.0	5.4	0.71
Fibrin-specific lytic, %	86.3	82.4	87.0	90.4	0.07
Initial heparin type, %					
None, %	8.0	10.3	6.5	2.3	0.34
UFH, %	40.1	38.3	34.1	67.0	
LMWH, %	48.5	49.0	53.6	23.4	
Both, %	3.4	2.3	5.7	7.3	
Angiography performed during index hospitalization, %	97.7	95.0	94.3	96.2	0.33

**Table S9:** Baseline characteristics by hsCRP quartile at baseline

<b>Variable</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>p-value (trend)</b>
Number	318	307	313	312	
Ranges (mg/L)	< 1.3	1.3-2.8	2.8-6.1	> 6.1	
Gender (male) , %	80.5	88.3	77.0	72.1	<0.001
Age (years), median	56	59	57	61	0.001
Weight (kg), median	77.0	80.0	80.0	80.0	<0.001
BMI, median	26.1	26.8	27.6	28.0	<0.001
History hypertension, %	33.4	40.2	36.3	47.7	0.002
History hyperlipidemia, %	40.8	39.8	42.4	39.9	0.99
History diabetes, %	13.2	13.8	18.8	23.6	<0.001
History CHF, %	0.3	0.7	1.3	2.9	0.003
Current tobacco use, %	40.7	46.9	54.5	47.3	0.03
Prior MI, %	9.8	6.5	8.7	8.7	0.86
Prior PCI, %	6.6	2.9	4.2	4.5	0.32
Anterior MI, %	39.0	35.8	36.1	39.1	0.97
CrCl, median	85.6	87.1	89.1	84.9	0.57
Sx onset to lytic (hrs), median	2.3	2.4	2.4	3.0	<0.001
Killip class 2-4, %	5.0	4.9	7.3	10.6	0.003
Fibrin-specific lytic, %	87.4	88.3	86.9	84.3	0.21
Initial heparin type, %					
None, %	6.3	5.9	6.7	9.0	0.91
UFH, %	45.9	46.3	44.1	43.3	
LMWH, %	43.7	43.6	43.8	42.6	
Both, %	4.1	4.2	5.4	5.1	
Angiography performed during index hospitalization, %	96.9	97.7	96.5	92.9	0.009

**Table S10:** Baseline characteristics by PAPP-A quartile at baseline

<b>Variable</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>p-value (trend)</b>
Number	219	219	219	219	
Ranges	< 2.4	2.4-4.4	4.4-16.2	> 16.2	
Gender (male) , %	68.5	80.4	84.9	82.6	<0.001
Age (years), median	57	58	57	60	0.25
Weight (kg), median	77.7	80.0	81.0	79.0	0.28
BMI, median	26.7	27.1	27.4	26.5	0.81
History hypertension, %	39.6	36.1	43.5	37.8	0.90
History hyperlipidemia, %	45.8	34.4	40.7	38.1	0.28
History diabetes, %	18.1	15.7	19.6	13.5	0.39
History CHF, %	0.5	0.9	0.9	1.4	0.34
Current tobacco use, %	52.1	51.1	42.0	44.5	0.04
Prior MI, %	6.9	7.3	9.2	7.8	0.59
Prior PCI, %	1.8	4.1	6.4	3.2	0.27
Anterior MI, %	33.3	47.5	42.5	33.8	0.80
CrCl, median	86.3	89.3	88.8	83.4	0.87
Sx onset to lytic (hrs), median	2.5	2.5	2.5	2.3	0.25
Killip class 2-4, %	5.9	7.3	5.0	6.0	0.76
Fibrin-specific lytic, %	85.8	79.9	87.7	95.0	<0.001
Initial Heparin type, %					
None, %	8.2	9.6	7.3	0.5	0.02
UFH, %	46.6	38.8	43.8	49.3	
LMWH, %	42.0	48.9	40.6	45.7	
Both, %	3.2	2.7	8.2	4.6	
Angiography performed during index hospitalization, %	95.9	96.8	96.3	95.0	0.59

**Table S11:** Baseline characteristics by GDF-15 quartile at baseline among

<b>Variable</b>	<b>Q1</b>	<b>Q2</b>	<b>Q3</b>	<b>Q4</b>	<b>p-value (trend)</b>
Number	278	278	278	277	
Ranges (pg/ml)	<539.6	539.6 - 784.3	784.3-1243.9	>1243.9	
Gender (male) , %	86.7	79.9	74.5	76.5	<0.001
Age (years), median	55.5	58	60	61	<0.001
Weight (kg), median	81.0	80.0	79.8	80.0	0.06
BMI, median	27.3	27.0	26.7	26.9	0.97
History hypertension, %	33.0	40.6	39.2	45.1	0.008
History hyperlipidemia, %	44.3	45.0	39.4	33.9	0.009
History diabetes, %	11.2	17.2	18.6	24.6	<0.001
History CHF, %	0.4	1.4	1.4	1.8	0.14
Current tobacco use, %	47.1	48.9	48.9	43.7	0.44
Prior MI, %	7.6	9.1	7.2	9.8	0.52
Prior PCI, %	5.0	4.0	4.3	4.0	0.61
Anterior MI, %	37.8	39.2	41.7	33.6	0.44
CrCl, median	97.7	88.5	83.3	75.9	<0.001
Sx onset to lytic (hrs), median	2.3	2.4	2.5	2.7	<0.001
Killip class 2-4, %	7.2	6.9	7.2	6.9	0.92
Fibrin-specific lytic, %	91.4	88.5	86.3	80.5	<0.001
Initial heparin type, %					
None, %	5.4	6.5	4.3	10.8	0.53
UFH, %	54.3	43.2	43.9	42.2	
LMWH, %	37.4	47.1	45.0	41.2	
Both, %	2.9	3.2	6.8	5.8	
Angiography performed during index hospitalization, %	98.2	96.4	96.0	92.1	<0.001

**Table S12:** Baseline characteristics by troponin T quantile at baseline

<b>Variable</b>	<b>Undetectable TnT</b>	<b>TnT Tertile 1 (if detectable)</b>	<b>TnT Tertile 2 (if detectable)</b>	<b>TnT Tertile 3 (if detectable)</b>	<b>p-value (trend)</b>
Number	594	219	219	218	
Ranges (ng/ml)	<0.01	0.01-0.06	0.06-0.25	>0.25	
Gender (male) , %	81.0	80.4	78.1	75.7	0.09
Age (years), median	56	59	60	62	<0.001
Weight (kg), median	80.0	80.0	80.0	78.5	0.32
BMI, median	27.1	27.1	27.3	26.8	0.70
History hypertension, %	35.7	35.9	45.2	47.2	<0.001
History hyperlipidemia, %	45.0	36.3	42.7	31.0	0.003
History diabetes, %	15.6	16.9	15.7	24.3	0.02
History CHF, %	0.8	0.9	1.4	2.8	0.05
Current tobacco use, %	50.4	44.3	46.8	42.4	0.05
Prior MI, %	10.0	6.8	7.8	6.5	0.10
Prior PCI, %	5.9	4.6	3.7	1.8	0.01
Anterior MI, %	27.4	41.1	48.4	50.5	<0.001
CrCl, median	88.9	91.5	84.5	79.8	<0.001
Sx onset to lytic (hrs), median	2.0	2.5	3.2	4.0	<0.001
Killip class 2-4, %	5.7	6.0	5.5	12.8	0.005
Fibrin-specific lytic, %	87.5	90.9	86.8	80.3	0.02
Initial Heparin type, %					
None, %	7.1	4.1	9.1	7.3	0.95
UFH, %	42.9	53.0	47.9	39.0	
LMWH, %	44.6	39.3	39.3	48.6	
Both, %	5.4	3.7	3.7	5.0	
Angiography performed during index hospitalization, %	97.6	98.6	96.3	88.5	<0.001

**Table S13:** The association between each candidate marker individually and the odds of CV death at 30 days after multivariable adjustment.

	<b>Biomarker</b>	<b>OR (95% CI) adjusted for clinical factors</b>	<b>P value</b>
<b>Myocardial stress/ structural changes</b>	NT-proBNP	2.92 (1.45-5.90)	0.003
	MR-pro ANP	2.22 (1.10-4.49)	0.03
	ST-2	2.63 (1.36-5.09)	0.004
	Galectin-3	1.68 (0.83-3.42)	0.15
	MR-pro adrenomedullin	1.12 (0.55-2.28)	0.75
	Copeptin	1.49 (0.74-3.02)	0.26
<b>Myo-necrosis</b>	Troponin T (T1-T2)*	3.85 (1.47-10.1)	0.006
	Troponin T (T3)*	6.72 (2.51-18.0)	<0.001
<b>Inflammation</b>	MPO	7.15 (1.60-32.0)	0.01
	hsCRP	2.38 (1.23-4.61)	0.01
	PAPP-A	2.85 (0.86-9.46)	0.09
	GDF-15	1.01 (0.38-2.68)	0.99

All markers modeled quartile 4:quartile 1-3 except MPO, GDF-15 and PAPP-A (quartile 2-4:quartile 1). Multivariable model included age, sex, prior HF, diabetes mellitus, prior MI, systolic blood pressure, heart rate, Killip class II-IV, type of lytic, anterior STEMI, creatinine clearance <60ml/min, time to lytic, treatment arm. \*Troponin T coded as 3-way variable with undetectable troponin T as referent and detectable troponin T coded by tertile (T).

**Table S14:** The association between each candidate marker individually and the odds of heart failure at 30 days after multivariable adjustment.

	<b>Biomarker</b>	<b>OR (95% CI) adjusted for clinical factors</b>	<b>P value</b>
<b>Myocardial stress/ Structural changes</b>	NT-proBNP	1.75 (0.83-3.71)	0.14
	MR-pro ANP	1.72 (0.81-3.64)	0.16
	ST-2	2.68 (1.35-5.36)	0.005
	Galectin-3	2.22 (1.04-4.71)	0.04
	MR-pro adrenomedullin	0.95 (0.43-2.08)	0.90
	Copeptin	0.89 (0.40-1.98)	0.77
<b>Myo-necrosis</b>	Troponin T (T1-T2)*	1.50 (0.63-3.55)	0.36
	Troponin T (T3)*	1.92 (0.76-4.88)	0.17
<b>Inflammation</b>	MPO	1.08 (0.44-2.65)	0.86
	hsCRP	1.44 (0.70-2.96)	0.32
	PAPP-A	2.57 (0.72-9.21)	0.15
	GDF-15	0.69 (0.30-1.60)	0.39

All markers modeled quartile 4:quartile 1-3 except MPO, GDF-15 and PAPP-A (quartile 2-4:quartile 1). Multivariable model included age, sex, prior HF, diabetes mellitus, prior MI, systolic blood pressure, heart rate, Killip class II-IV, anterior STEMI, type of lytic, creatinine clearance <60ml/min, time to lytic, treatment arm. \*Troponin T coded as 3-way variable with undetectable troponin T as referent and detectable troponin T coded by tertile (T).

**Table S15:** The association between each candidate marker individually and the odds of MI at 30 days after multivariable adjustment.

	<b>Biomarker</b>	<b>OR (95% CI) adjusted for clinical factors</b>	<b>P value</b>
<b>Myocardial stress/ Structural changes</b>	NT-proBNP	0.66 (0.32-1.35)	0.25
	MR-pro ANP	1.09 (0.58-2.03)	0.79
	ST-2	1.70 (1.01-2.86)	0.046
	Galectin-3	1.02 (0.55-1.92)	0.94
	MR-pro adrenomedullin	0.85 (0.43-1.67)	0.64
	Copeptin	1.89 (1.08-3.30)	0.03
<b>Myo-necrosis</b>	Troponin T (T1-T2)*	0.75 (0.43-1.31)	0.31
	Troponin T (T3)*	0.57 (0.22-1.43)	0.23
<b>Inflammation</b>	MPO	1.00 (0.56-1.77)	0.99
	hsCRP	0.67 (0.35-1.29)	0.23
	PAPP-A	1.04 (0.51-2.11)	0.91
	GDF-15	0.32 (0.19-0.54)	<0.001

All markers modeled quartile 4:quartile 1-3 except MPO, GDF-15 and PAPP-A (quartile 2-4:quartile 1). Multivariable model included age, sex, prior HF, diabetes mellitus, prior MI, systolic blood pressure, heart rate, Killip class II-IV, anterior STEMI, type of lytic, creatinine clearance <60ml/min, time to lytic, treatment arm. \*Troponin T coded as 3-way variable with undetectable troponin T as referent and detectable troponin T coded by tertile (T).



**Table S16:** The association between each candidate marker individually and the odds of recurrent ischemia requiring urgent revascularization at 30 days after multivariable adjustment.

	<b>Biomarker</b>	<b>OR (95% CI) adjusted for clinical factors</b>	<b>P value</b>
<b>Myocardial stress/ Structural changes</b>	NT-proBNP	0.61 (0.28-1.31)	0.20
	MR-pro ANP	1.28 (0.63-2.59)	0.50
	ST-2	1.38 (0.75-2.52)	0.30
	Galectin-3	0.66 (0.29-1.49)	0.31
	MR-pro adrenomedullin	1.22 (0.59-2.49)	0.59
	Copeptin	0.59 (0.26-1.32)	0.20
<b>Myo-necrosis</b>	Troponin T (T1-T2)*	1.49 (0.80-2.76)	0.21
	Troponin T (T3)*	0.69 (0.25-1.88)	0.47
<b>Inflammation</b>	MPO	1.01 (0.50-2.01)	0.99
	hsCRP	1.10 (0.58-2.08)	0.77
	PAPP-A	1.40 (0.59-3.33)	0.44
	GDF-15	0.42 (0.22-0.80)	0.009

All markers modeled quartile 4:quartile 1-3 except MPO, GDF-15 and PAPP-A (quartile 2-4:quartile 1). Multivariable model included age, sex, prior HF, diabetes mellitus, prior MI, systolic blood pressure, heart rate, Killip class II-IV, anterior STEMI, type of lytic, creatinine clearance <60ml/min, time to lytic, treatment arm. \*Troponin T coded as 3-way variable with undetectable troponin T as referent and detectable troponin T coded by tertile (T).

**Table S17:** The association between each candidate marker individually and the odds of TIMI flow grade 0 or 1 at angiography after multivariable adjustment.

	<b>Biomarker</b>	<b>OR (95% CI) adjusted for clinical factors</b>	<b>P value</b>
<b>Myocardial stress/ Structural changes</b>	NT-proBNP	1.27 (0.82-1.96)	0.29
	MR-pro ANP	1.16 (0.73-1.85)	0.53
	ST-2	1.72 (1.18-2.50)	0.006
	Galectin-3	1.03 (0.65-1.64)	0.89
	MR-pro adrenomedullin	0.97 (0.61-1.56)	0.91
	Copeptin	1.55 (1.01-2.39)	0.045
<b>Myo-necrosis</b>	Troponin T (T1-T2)*	1.08 (0.71-1.61)	0.73
	Troponin T (T3)*	1.52 (0.88-2.56)	0.13
<b>Inflammation</b>	MPO	1.45 (0.90-2.33)	0.12
	hsCRP	1.41 (0.94-2.08)	0.10
	PAPP-A	1.47 (0.81-2.70)	0.21
	GDF-15	0.41 (0.27-0.62)	<0.001

All markers modeled quartile 4:quartile 1-3 except MPO, GDF-15 and PAPP-A (quartile 2-4:quartile 1). Multivariable model included age, sex, prior HF, diabetes mellitus, prior MI, systolic blood pressure, heart rate, Killip class II-IV, anterior STEMI, type of lytic, creatinine clearance <60ml/min, time to lytic, treatment arm. \*Troponin T coded as 3-way variable with undetectable troponin T as referent and detectable troponin T coded by tertile (T).

**Table S18:** The association between ST2, troponin T and MPO and the odds of CV death or HF at 30 days after multivariable adjustment including left ventricular ejection fraction (LVEF) in the 515 subjects in whom LVEF was available.

<b>Biomarker</b>	<b>OR (95% CI) adjusted for clinical factors</b>
ST2	4.60 (1.69-12.5)
Troponin T (Tertile 1-2)	5.28 (1.21-23.0)
Troponin T (Tertile 3)	8.14 (1.74-38..0)
MPO	2.01 (0.53-7.67)

\*Troponin T coded as 3-way variable with undetectable troponin T as referent and detectable troponin T coded by tertile (T).